Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial

INTRODUCTION: The CoronaVac vaccine is widely used in Thailand to combat the coronavirus disease 2019 (COVID-19) pandemic. The limited immunogenicity of this vaccine is a concern, especially because of expanding delta variant outbreaks. A third boost may enhance antiviral immune responses. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Tawinprai, Kriangkrai, Siripongboonsitti, Taweegrit, Porntharukchareon, Thachanun, Wittayasak, Kasiruck, Thonwirak, Nawarat, Soonklang, Kamonwan, Sornsamdang, Gaidganok, Auewarakul, Chirayu, Mahanonda, Nithi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860330/
https://www.ncbi.nlm.nih.gov/pubmed/35210118
http://dx.doi.org/10.1016/j.vaccine.2022.02.019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860330/
https://www.ncbi.nlm.nih.gov/pubmed/35210118
http://dx.doi.org/10.1016/j.vaccine.2022.02.019

Ejemplares similares